Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-infected subjects in the Czech Republic

David Jilich; Milena Vraná; Svatava Snopková; Dalibor Sedlácek; Jaroslav Kapla; Hanus Rozsypal; Jitka Kolcáková; Lenka Olbrechtová; Alena Zjevíková; Zdenka Jerhotová; Marek Malý; Marie Stanková; Ladislav Machala

doi:10.21101/cejph.a3653

Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-infected subjects in the Czech Republic

Cent Eur J Public Health. 2011 Sep;19(3):128-30. doi: 10.21101/cejph.a3653.

Authors

David Jilich¹, Milena Vraná, Svatava Snopková, Dalibor Sedlácek, Jaroslav Kapla, Hanus Rozsypal, Jitka Kolcáková, Lenka Olbrechtová, Alena Zjevíková, Zdenka Jerhotová, Marek Malý, Marie Stanková, Ladislav Machala

Affiliation

¹ Department of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University in Prague, Czech Republic.

PMID: 22026283
DOI: 10.21101/cejph.a3653

Abstract

The HLA-B*57:01 allele is associated with a hypersensitivity reaction to abacavir, and its prevalence varies in different populations. The aim of the study was to investigate HLA-B*57:01 prevalence in the Czech HIV-infected population. HLA-B*57:01 prevalence in our cohort was 5.33%, which is similar to the situation in other Central European countries.

MeSH terms

Anti-HIV Agents / adverse effects
Cross-Sectional Studies
Czech Republic / epidemiology
Dideoxynucleosides / adverse effects
Drug Hypersensitivity / diagnosis
Drug Hypersensitivity / epidemiology*
HIV Infections / blood
HIV Infections / drug therapy
HLA-B Antigens* / blood
Humans
Prevalence

Substances

Anti-HIV Agents
Dideoxynucleosides
HLA-B Antigens
HLA-B*57:01 antigen
abacavir